<?xml version="1.0"?>
<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.4 20190208//EN"
       "JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="1.4" xml:lang="en">
 <front>
  <journal-meta>
   <journal-id journal-id-type="publisher-id">Medical Radiology and radiation safety</journal-id>
   <journal-title-group>
    <journal-title xml:lang="en">Medical Radiology and radiation safety</journal-title>
    <trans-title-group xml:lang="ru">
     <trans-title>Медицинская радиология и радиационная безопасность</trans-title>
    </trans-title-group>
   </journal-title-group>
   <issn publication-format="print">1024-6177</issn>
   <issn publication-format="online">2618-9615</issn>
  </journal-meta>
  <article-meta>
   <article-id pub-id-type="publisher-id">46746</article-id>
   <article-id pub-id-type="doi">10.12737/1024-6177-2021-66-5-95-100</article-id>
   <article-categories>
    <subj-group subj-group-type="toc-heading" xml:lang="ru">
     <subject>Радиационная физика, техника и дозиметрия</subject>
    </subj-group>
    <subj-group subj-group-type="toc-heading" xml:lang="en">
     <subject>Radiation physics, technology and dosimetry</subject>
    </subj-group>
    <subj-group>
     <subject>Радиационная физика, техника и дозиметрия</subject>
    </subj-group>
   </article-categories>
   <title-group>
    <article-title xml:lang="en">Estimation of Radiotherapy Efficiency of Head-and-Neck Cancer Based</article-title>
    <trans-title-group xml:lang="ru">
     <trans-title>ОЦЕНКА ЭФФЕКТИВНОСТИ ЛУЧЕВОЙ ТЕРАПИИ РАКА ГОЛОВЫ-ШЕИ НА  ОСНОВЕ МОДЕЛИ ЛОКАЛЬНОГО КОНТРОЛЯ ОПУХОЛИ</trans-title>
    </trans-title-group>
   </title-group>
   <contrib-group content-type="authors">
    <contrib contrib-type="author">
     <name-alternatives>
      <name xml:lang="ru">
       <surname>Сухих</surname>
       <given-names>Е. С.</given-names>
      </name>
      <name xml:lang="en">
       <surname>Sukhikh</surname>
       <given-names>E. S.</given-names>
      </name>
     </name-alternatives>
     <bio xml:lang="ru">
      <p>кандидат физико-математических наук;</p>
     </bio>
     <bio xml:lang="en">
      <p>candidate of physical and mathematical sciences;</p>
     </bio>
     <xref ref-type="aff" rid="aff-1"/>
     <xref ref-type="aff" rid="aff-2"/>
    </contrib>
    <contrib contrib-type="author">
     <name-alternatives>
      <name xml:lang="ru">
       <surname>Сухих</surname>
       <given-names>Л. Г.</given-names>
      </name>
      <name xml:lang="en">
       <surname>Sukhikh</surname>
       <given-names>L. G</given-names>
      </name>
     </name-alternatives>
     <bio xml:lang="ru">
      <p>доктор физико-математических наук;</p>
     </bio>
     <bio xml:lang="en">
      <p>doctor of physical and mathematical sciences;</p>
     </bio>
     <xref ref-type="aff" rid="aff-3"/>
    </contrib>
    <contrib contrib-type="author">
     <name-alternatives>
      <name xml:lang="ru">
       <surname>Сутыгина</surname>
       <given-names>Я. Н.</given-names>
      </name>
      <name xml:lang="en">
       <surname>Sutygina</surname>
       <given-names>Ya. N.</given-names>
      </name>
     </name-alternatives>
     <xref ref-type="aff" rid="aff-4"/>
     <xref ref-type="aff" rid="aff-5"/>
    </contrib>
    <contrib contrib-type="author">
     <name-alternatives>
      <name xml:lang="ru">
       <surname>Ижевский</surname>
       <given-names>П. В.</given-names>
      </name>
      <name xml:lang="en">
       <surname>Izhevsky</surname>
       <given-names>P. V.</given-names>
      </name>
     </name-alternatives>
     <bio xml:lang="ru">
      <p>кандидат медицинских наук;</p>
     </bio>
     <bio xml:lang="en">
      <p>candidate of medical sciences;</p>
     </bio>
     <xref ref-type="aff" rid="aff-6"/>
    </contrib>
    <contrib contrib-type="author">
     <name-alternatives>
      <name xml:lang="ru">
       <surname>Шейно</surname>
       <given-names>И. Н.</given-names>
      </name>
      <name xml:lang="en">
       <surname>Sheino</surname>
       <given-names>I. N.</given-names>
      </name>
     </name-alternatives>
     <bio xml:lang="ru">
      <p>кандидат физико-математических наук;</p>
     </bio>
     <bio xml:lang="en">
      <p>candidate of physical and mathematical sciences;</p>
     </bio>
     <xref ref-type="aff" rid="aff-7"/>
    </contrib>
    <contrib contrib-type="author">
     <name-alternatives>
      <name xml:lang="ru">
       <surname>Стахова</surname>
       <given-names>О. М.</given-names>
      </name>
      <name xml:lang="en">
       <surname>Stakhova</surname>
       <given-names>O. M.</given-names>
      </name>
     </name-alternatives>
     <xref ref-type="aff" rid="aff-8"/>
     <xref ref-type="aff" rid="aff-9"/>
    </contrib>
    <contrib contrib-type="author">
     <name-alternatives>
      <name xml:lang="ru">
       <surname>Клиновицкая</surname>
       <given-names>М. И.</given-names>
      </name>
      <name xml:lang="en">
       <surname>Klinovitskaya</surname>
       <given-names>M. I.</given-names>
      </name>
     </name-alternatives>
     <xref ref-type="aff" rid="aff-10"/>
    </contrib>
   </contrib-group>
   <aff-alternatives id="aff-1">
    <aff>
     <institution xml:lang="ru">Томский областной онкологический диспансер</institution>
     <city>Томск</city>
     <country>Россия</country>
    </aff>
    <aff>
     <institution xml:lang="en">Tomsk Regional Oncology Center</institution>
     <city>Tomsk</city>
     <country>Russian Federation</country>
    </aff>
   </aff-alternatives>
   <aff-alternatives id="aff-2">
    <aff>
     <institution xml:lang="ru">Национальный исследовательский Томский политехнический университет, Томск</institution>
     <country>Россия</country>
    </aff>
    <aff>
     <institution xml:lang="en">National Research Tomsk Polytechnic University, Tomsk, Russia</institution>
     <country>Russian Federation</country>
    </aff>
   </aff-alternatives>
   <aff-alternatives id="aff-3">
    <aff>
     <institution xml:lang="ru">Национальный исследовательский Томский политехнический университет</institution>
     <city>Томск</city>
     <country>Россия</country>
    </aff>
    <aff>
     <institution xml:lang="en">National Research Tomsk Polytechnic University</institution>
     <city>Tomsk</city>
     <country>Russian Federation</country>
    </aff>
   </aff-alternatives>
   <aff-alternatives id="aff-4">
    <aff>
     <institution xml:lang="ru">Томский областной онкологический диспансер, Томск</institution>
     <country>Россия</country>
    </aff>
    <aff>
     <institution xml:lang="en">Tomsk Regional Oncology Center, Tomsk, Russia</institution>
     <country>Russian Federation</country>
    </aff>
   </aff-alternatives>
   <aff-alternatives id="aff-5">
    <aff>
     <institution xml:lang="ru">Национальный ­исследовательский Томский политехнический университет, Томск</institution>
     <country>Россия</country>
    </aff>
    <aff>
     <institution xml:lang="en">National Research Tomsk Polytechnic University, Tomsk, Russia</institution>
     <country>Russian Federation</country>
    </aff>
   </aff-alternatives>
   <aff-alternatives id="aff-6">
    <aff>
     <institution xml:lang="ru">Федеральный медицинский биофизический центр им. А.И. Бурназяна ФМБА России</institution>
     <city>Москва</city>
     <country>Россия</country>
    </aff>
    <aff>
     <institution xml:lang="en">A.I. Burnasyan Federal Medical Biophysical Center of FMBA</institution>
     <city>Moscow</city>
     <country>Russian Federation</country>
    </aff>
   </aff-alternatives>
   <aff-alternatives id="aff-7">
    <aff>
     <institution xml:lang="ru">Федеральный медицинский биофизический центр им. А.И. Бурназяна ФМБА России</institution>
     <city>Москва</city>
     <country>Россия</country>
    </aff>
    <aff>
     <institution xml:lang="en">A.I. Burnasyan Federal Medical Biophysical Center of FMBA</institution>
     <city>Moscow</city>
     <country>Russian Federation</country>
    </aff>
   </aff-alternatives>
   <aff-alternatives id="aff-8">
    <aff>
     <institution xml:lang="ru">Национальный ­исследовательский Томский политехнический университет, Томск</institution>
     <country>Россия</country>
    </aff>
    <aff>
     <institution xml:lang="en">National Research Tomsk Polytechnic University, Tomsk, Russia</institution>
     <country>Russian Federation</country>
    </aff>
   </aff-alternatives>
   <aff-alternatives id="aff-9">
    <aff>
     <institution xml:lang="ru">Многопрофильный клинический медицинский центр «Медицинский город», Тюмень</institution>
     <country>Россия</country>
    </aff>
    <aff>
     <institution xml:lang="en">Multidisciplinary Clinical Medical Ccenter “Medical city”, Tyumen,  Russia</institution>
     <country>Russian Federation</country>
    </aff>
   </aff-alternatives>
   <aff-alternatives id="aff-10">
    <aff>
     <institution xml:lang="ru">Национальный ­исследовательский Томский политехнический университет, Томск</institution>
     <country>Россия</country>
    </aff>
    <aff>
     <institution xml:lang="en">National Research Tomsk Polytechnic University, Tomsk, Russia</institution>
     <country>Russian Federation</country>
    </aff>
   </aff-alternatives>
   <volume>66</volume>
   <issue>5</issue>
   <fpage>95</fpage>
   <lpage>100</lpage>
   <history>
    <date date-type="received" iso-8601-date="2021-11-02T00:00:00+03:00">
     <day>02</day>
     <month>11</month>
     <year>2021</year>
    </date>
   </history>
   <self-uri xlink:href="https://zh-szf.ru/en/nauka/article/46746/view">https://zh-szf.ru/en/nauka/article/46746/view</self-uri>
   <abstract xml:lang="ru">
    <p>Цель:  Оценка ожидаемой эффективности лучевой терапии (ЛТ) на основе моделей вероятности локального контроля опухоли (TCP) для органов головы–шеи.&#13;
Материалы и методы: В рамках исследования использовались данные 11 пациентов с местнораспространёнными опухолями головы–шеи (гортань, ротоглотка и ротовая полость). Для каждого пациента разработаны два курса ЛТ с различными режимами фракционирования при использовании объёмно-модулированной дуговой терапии (VMAT): одновременной интегрированной эскалации дозы SIB-VMAT (70 Гр на опухоль, 50 Гр на лимфатические узлы, 25 фракций) и последовательный буст SEQ-VMAT (70 Гр на опухоль, 50 Гр на лимфатические узлы, 35 фракций). Разработанные планы проанализированы с использованием модели А. Niemierko с параметрами, полученными B. Maciejewski на основе гистограмм доза–объем и планируемого времени лечения.&#13;
Результаты: Разработанные планы позволили получить высокий уровень покрытия клинического объема опухоли (98–98 %) у всех пациентов, кроме одного. Среднее значение TCP для SIB-VMAT оценивается равным 99,9 % из-за слишком короткой общей продолжительности лечения. Среднее значение TCP для SEQ-VMAT равно 61,0 %. Для одного пациента оба плана SIB-VMAT и SEQ-VMAT показали нулевое ожидаемое значение эффективности ЛТ в связи с низким покрытием клинического объёма опухоли 95–95 %. &#13;
Заключение: Использование модели TCP позволяет проводить анализ планов персонифицированной лучевой терапии и разрабатывать адаптированные схемы лечения с увеличением величины суммарной дозы, дозы за фракцию с одновременным уменьшением общей продолжительности, терапии</p>
   </abstract>
   <trans-abstract xml:lang="en">
    <p>Purpose: Evaluation of the expected effectiveness of radiation therapy based on models of the local tumor control probability (Tumor Control Probability – TCP) for the head-neck cancer. &#13;
Material and methods: The study used data from 11 patients with locally advanced head-neck cancer (larynx, oropharynx, and oral cavity). For each patient two dosimetric treatment plans have been prepared: SIB-VMAT (70 Gy per tumor, 50 Gy per lymph nodes, 25 fractions) and SEQ-VMAT (70 Gy per tumor, 50 Gy per lymph nodes, 35 fractions). The developed plans were analyzed using A. Niemierko's TCP model with parameters obtained by B. Maciejewski (TCD50 = 70.26 Gy with a 49-day total treatment time), taking into account the dose–volume histograms and the total treatment time.&#13;
Results: The developed plans ensured a high level of coverage (98–98 %) of the Clinical treatment volume (CTV) in all but one patient. The average TCP SIB-VMAT is 99.9 % due to the very short total treatment time. The average TCP for SEQ-VMAT is 61.0%. For one patient, both SIB-VMAT and SEQ-VMAT showed zero expected efficacy due to 95–95 % CTV coverage.&#13;
Conclusion: The use of TCP model allows analyzing personalized treatment plans for patients and developing adaptive treatment regimens with an increase in the total dose, dose per fraction, and a decrease in the total treatment time.</p>
   </trans-abstract>
   <kwd-group xml:lang="ru">
    <kwd>местнораспространённый рак</kwd>
    <kwd>органы головы и шеи</kwd>
    <kwd>объемно-модулированная дуговая терапия</kwd>
    <kwd>локальный  контроль опухоли</kwd>
    <kwd>модель вероятности</kwd>
   </kwd-group>
   <kwd-group xml:lang="en">
    <kwd>locally advanced cancer head and neck</kwd>
    <kwd>volumetric modulated arc therapy</kwd>
    <kwd>simultaneous integrated dose escalation</kwd>
    <kwd>tumor control probability</kwd>
    <kwd>TCP model</kwd>
   </kwd-group>
  </article-meta>
 </front>
 <body>
  <p></p>
 </body>
 <back>
  <ref-list>
   <ref id="B1">
    <label>1.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Каприн А.Д, Старинский В.В, Петрова Г.В. Злокачественные новообразования в России в 2017 году. Заболеваемость и смертность. 2018. Available from: http://www.oncology.ru/service/statistics/malignant_tumors/2017.pdf.</mixed-citation>
     <mixed-citation xml:lang="en">Kaprin A.D, Starinskiy V.V, Petrova G.V. Zlokachestvennye novoobrazovaniya v Rossii v 2017 godu. Zabolevaemost' i smertnost'. 2018. Available from: http://www.oncology.ru/service/statistics/malignant_tumors/2017.pdf.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B2">
    <label>2.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Beitler JJ, Zhang Q, Fu KK, Trotti A, Spencer SA, Jones CU, et al. Final Results of Local-Regional Control and Late Toxicity of RTOG 9003: A Randomized Trial of Altered Fractionation Radiation for Locally Advanced Head and Neck Cancer // International Journal of Radiation Oncology Biology Physics. 2014. V.89, No. 1. P. 13-20. DOI: 10.1016/j.ijrobp.2013.12.027. PMID: 24613816.</mixed-citation>
     <mixed-citation xml:lang="en">Beitler JJ, Zhang Q, Fu KK, Trotti A, Spencer SA, Jones CU, et al. Final Results of Local-Regional Control and Late Toxicity of RTOG 9003: A Randomized Trial of Altered Fractionation Radiation for Locally Advanced Head and Neck Cancer // International Journal of Radiation Oncology Biology Physics. 2014. V.89, No. 1. P. 13-20. DOI: 10.1016/j.ijrobp.2013.12.027. PMID: 24613816.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B3">
    <label>3.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Dragan T., Beauvois S, Moreau M, Paesmans M, Vandekerkhove C, Cordier L, et al. Clinical Outcome and Toxicity after Simultaneous Integrated Boost IMRT in Head and Neck Squamous Cell Cancer Patients // Oral Oncology. 2019. No. 98. P. 132-140. DOI: 10.1016/j.oraloncology.2019.09.012. DOI: 10.1016/j.oraloncology.2019.09.012. PMID: 31586895.</mixed-citation>
     <mixed-citation xml:lang="en">Dragan T., Beauvois S, Moreau M, Paesmans M, Vandekerkhove C, Cordier L, et al. Clinical Outcome and Toxicity after Simultaneous Integrated Boost IMRT in Head and Neck Squamous Cell Cancer Patients // Oral Oncology. 2019. No. 98. P. 132-140. DOI: 10.1016/j.oraloncology.2019.09.012. DOI: 10.1016/j.oraloncology.2019.09.012. PMID: 31586895.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B4">
    <label>4.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Maciejewski B, Withers HR, Taylor JMG, Hliniak A. Dose Fractionation and Regeneration in Radiotherapy for Cancer of the Oral Cavity and Oropharynx: Tumor Dose-Response and Repopulation // International Journal of Radiation Oncology, Biology, Physics. 1989. V.16, No. 3. P. 831-843. DOI: 10.1016/0360-3016(89)90503-8. PMID: 2921175.</mixed-citation>
     <mixed-citation xml:lang="en">Maciejewski B, Withers HR, Taylor JMG, Hliniak A. Dose Fractionation and Regeneration in Radiotherapy for Cancer of the Oral Cavity and Oropharynx: Tumor Dose-Response and Repopulation // International Journal of Radiation Oncology, Biology, Physics. 1989. V.16, No. 3. P. 831-843. DOI: 10.1016/0360-3016(89)90503-8. PMID: 2921175.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B5">
    <label>5.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Orlandi E, Palazzi M, Pignoli E, Fallai C, Giostra A, Olmi P. Radiobiological Basis and Clinical Results of the Simultaneous Integrated Boost (SIB) in Intensity Modulated Radiotherapy (IMRT) for Head and Neck Cancer: A Review // Critical Reviews in Oncology/Hematology. 2010. V.73, No. 2. P. 111-125. DOI: 10.1016/j.critrevonc.2009.03.003. PMID: 19409808.</mixed-citation>
     <mixed-citation xml:lang="en">Orlandi E, Palazzi M, Pignoli E, Fallai C, Giostra A, Olmi P. Radiobiological Basis and Clinical Results of the Simultaneous Integrated Boost (SIB) in Intensity Modulated Radiotherapy (IMRT) for Head and Neck Cancer: A Review // Critical Reviews in Oncology/Hematology. 2010. V.73, No. 2. P. 111-125. DOI: 10.1016/j.critrevonc.2009.03.003. PMID: 19409808.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B6">
    <label>6.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Chao KSC, Ozyigit G, Tran BN, Cengiz M, Dempsey JF, Low DA. Patterns of Failure in Patients Receiving Deﬁnitive and Postoperative IMRT for Head-and-Neck Cancer // International Journal of Radiation Oncology Biology Physics. 2003. V.55, No. 2. P. 312-321. DOI: 10.1016/s0360 -3016(02)03940-8. PMID: 12527043.</mixed-citation>
     <mixed-citation xml:lang="en">Chao KSC, Ozyigit G, Tran BN, Cengiz M, Dempsey JF, Low DA. Patterns of Failure in Patients Receiving Deﬁnitive and Postoperative IMRT for Head-and-Neck Cancer // International Journal of Radiation Oncology Biology Physics. 2003. V.55, No. 2. P. 312-321. DOI: 10.1016/s0360 -3016(02)03940-8. PMID: 12527043.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B7">
    <label>7.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Spiotto MT, Weichselbaum RR Comparison of 3D Confromal Radiotherapy and Intensity Modulated Radiotherapy with or Without Simultaneous Integrated Boost During Concurrent Chemoradiation for Locally Advanced Head and Neck Cancers // PLoS ONE. 2014. V.9, No. 4. DOI: 10.1371/journal.pone.0094456. PMID: 24714187.</mixed-citation>
     <mixed-citation xml:lang="en">Spiotto MT, Weichselbaum RR Comparison of 3D Confromal Radiotherapy and Intensity Modulated Radiotherapy with or Without Simultaneous Integrated Boost During Concurrent Chemoradiation for Locally Advanced Head and Neck Cancers // PLoS ONE. 2014. V.9, No. 4. DOI: 10.1371/journal.pone.0094456. PMID: 24714187.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B8">
    <label>8.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Vlacich G, Stavas MJ, Pendyala P, Chen SC, Shyr Y, Cmelak AJ. A Comparative Analysis Between Sequential Boost and Integrated Boost Intensity-Modulated Radiation Therapy with Concurrent Chemotherapy for Locally-Advanced Head and Neck Cancer // Radiation Oncology. 2017. V.12, No. 1. DOI: 10.1186/s13014-016-0756-x. PMID: 28086954.</mixed-citation>
     <mixed-citation xml:lang="en">Vlacich G, Stavas MJ, Pendyala P, Chen SC, Shyr Y, Cmelak AJ. A Comparative Analysis Between Sequential Boost and Integrated Boost Intensity-Modulated Radiation Therapy with Concurrent Chemotherapy for Locally-Advanced Head and Neck Cancer // Radiation Oncology. 2017. V.12, No. 1. DOI: 10.1186/s13014-016-0756-x. PMID: 28086954.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B9">
    <label>9.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Vanasek J, Odrazka K, Dusek L, Jarkovsky J, Michalek R, Chrobok V, et al. Experience with Intensity-Modulated Radiotherapy in the Treatment of Head and Neck Cancer // Journal of BUON. 2013. V.18, No. 4. P. 970-976. PMID: 24344025.</mixed-citation>
     <mixed-citation xml:lang="en">Vanasek J, Odrazka K, Dusek L, Jarkovsky J, Michalek R, Chrobok V, et al. Experience with Intensity-Modulated Radiotherapy in the Treatment of Head and Neck Cancer // Journal of BUON. 2013. V.18, No. 4. P. 970-976. PMID: 24344025.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B10">
    <label>10.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Farrag A, Voordeckers M, Tournel K, De Coninck P, Storme G. Pattern of Failure after Helical Tomotherapy in Head and Neck Cancer // Strahlentherapie und Onkologie. 2010. V.186, No. 9. P. 511-516. DOI: 10.1007/s00066-010-2130-5. PMID: 20803182.</mixed-citation>
     <mixed-citation xml:lang="en">Farrag A, Voordeckers M, Tournel K, De Coninck P, Storme G. Pattern of Failure after Helical Tomotherapy in Head and Neck Cancer // Strahlentherapie und Onkologie. 2010. V.186, No. 9. P. 511-516. DOI: 10.1007/s00066-010-2130-5. PMID: 20803182.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B11">
    <label>11.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Barry MA, Hussein M, Schettino G. Evaluating the Propagation of Uncertainties in Biologically Based Treatment Planning Parameters // Front. Oncol. 2020. DOI: 10.3389/fonc.2020.01058. PMID: 32793468.</mixed-citation>
     <mixed-citation xml:lang="en">Barry MA, Hussein M, Schettino G. Evaluating the Propagation of Uncertainties in Biologically Based Treatment Planning Parameters // Front. Oncol. 2020. DOI: 10.3389/fonc.2020.01058. PMID: 32793468.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B12">
    <label>12.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Niemierko A. Reporting and Analyzing Dose Distributions: A Concept of Equivalent Uniform Dose // Medical Physics. 1997. V.24, No. 1. P. 103-110. DOI: 10.1118/1.598063. PMID: 9029544.</mixed-citation>
     <mixed-citation xml:lang="en">Niemierko A. Reporting and Analyzing Dose Distributions: A Concept of Equivalent Uniform Dose // Medical Physics. 1997. V.24, No. 1. P. 103-110. DOI: 10.1118/1.598063. PMID: 9029544.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B13">
    <label>13.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Gay HA., Niemierko A A. Free Program for Calculating EUD-Based NTCP and TCP in External Beam Radiotherapy // Physica Medica. 2007. No. 3-4. P. 115-125. DOI: 10.1016/j.ejmp.2007.07.001. PMID: 17825595.</mixed-citation>
     <mixed-citation xml:lang="en">Gay HA., Niemierko A A. Free Program for Calculating EUD-Based NTCP and TCP in External Beam Radiotherapy // Physica Medica. 2007. No. 3-4. P. 115-125. DOI: 10.1016/j.ejmp.2007.07.001. PMID: 17825595.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B14">
    <label>14.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Bigelow EO, Seiwert TY, Fakhry C. Deintensiﬁcation of Treatment for Human Papillomavirus-Related Oropharyngeal Cancer: Current State and Future Directions // Oral Oncology. 2020. No. 105. DOI: 10.1016/j.oraloncology.2020.104652. PMID: 32247987.</mixed-citation>
     <mixed-citation xml:lang="en">Bigelow EO, Seiwert TY, Fakhry C. Deintensiﬁcation of Treatment for Human Papillomavirus-Related Oropharyngeal Cancer: Current State and Future Directions // Oral Oncology. 2020. No. 105. DOI: 10.1016/j.oraloncology.2020.104652. PMID: 32247987.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B15">
    <label>15.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Fakhry C, Zhang Q, Gillison ML, Nguyen-Tân PF, Rosenthal DI, Weber RS, et al. Validation of NRG Oncology/RTOG-0129 Risk Groups for HPV-Positive and HPV-Negative Oropharyngeal Squamous Cell Cancer: Implications for Risk-Based Therapeutic Intensity Trials // Cancer. 2019. V.125, No. 12. P. 2027-2038. DOI: 10.1002/cncr.32025. PMID: 30913305.</mixed-citation>
     <mixed-citation xml:lang="en">Fakhry C, Zhang Q, Gillison ML, Nguyen-Tân PF, Rosenthal DI, Weber RS, et al. Validation of NRG Oncology/RTOG-0129 Risk Groups for HPV-Positive and HPV-Negative Oropharyngeal Squamous Cell Cancer: Implications for Risk-Based Therapeutic Intensity Trials // Cancer. 2019. V.125, No. 12. P. 2027-2038. DOI: 10.1002/cncr.32025. PMID: 30913305.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B16">
    <label>16.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Overgaard J, Hansen HS, Specht L, Overgaard M, Grau C, Andersen E, et al. Five Compared with Six Fractions Per Week of Conventional Radiotherapy of Squamous-Cell Carcinoma of Head and Neck: DAHANCA 6&amp;7 Randomised Controlled Trial // Lancet. 2003. V.362, No. 9388. P. 933-940. DOI: 10.1016/s0140-6736(03)14361-9. PMID: 14511925.</mixed-citation>
     <mixed-citation xml:lang="en">Overgaard J, Hansen HS, Specht L, Overgaard M, Grau C, Andersen E, et al. Five Compared with Six Fractions Per Week of Conventional Radiotherapy of Squamous-Cell Carcinoma of Head and Neck: DAHANCA 6&amp;7 Randomised Controlled Trial // Lancet. 2003. V.362, No. 9388. P. 933-940. DOI: 10.1016/s0140-6736(03)14361-9. PMID: 14511925.</mixed-citation>
    </citation-alternatives>
   </ref>
  </ref-list>
 </back>
</article>
